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A B S T R A C T   
Objective: To compare and characterize major depressive disorder (MDD) subtypes (i.e., pure atypical, pure 
melancholic and mixed atypical-melancholic) and depression symptoms in persons with multiple sclerosis 
(PwMS) with persons without MS (Pw/oMS) fulfilling the DSM-5 criteria for a past 12-month MDD. 
Methods: MDD in PwMS (n = 92) from the Swiss Multiple Sclerosis Registry was compared with Pw/oMS (n =
277) from a Swiss community-based study. Epidemiological MDD diagnoses were based on the Mini-SPIKE 
(shortened form of the Structured Psychopathological Interview and Rating of the Social Consequences for 
Epidemiology). Logistic and multinomial regression analyses (adjusted for sex, age, civil status, depression and 
severity) were computed for comparisons and characterization. Latent class analysis (LCA) was conducted to 
empirically identify depression subtypes in PwMS. 
Results: PwMS had a higher risk for the mixed atypical-melancholic MDD subtype (OR = 2.22, 95% CI =
1.03–4.80) compared to Pw/oMS. MDD in PwMS was specifically characterized by a higher risk of the two so-
matic atypical depression symptoms ‘weight gain’ (OR = 6.91, 95% CI = 2.20–21.70) and ‘leaden paralysis’ (OR 
= 3.03, 95% CI = 1.35–6.82) and the symptom ‘irritable/angry’ (OR = 3.18, 95% CI = 1.08–9.39). 
Conclusions: MDD in PwMS was characterized by a higher risk for specific somatic atypical depression symptoms 
and the mixed atypical-melancholic MDD subtype. The pure atypical MDD subtype, however, did not differen-
tiate between PwMS and Pw/oMS. Given the high phenomenological overlap with MS symptoms, the mixed 
atypical-melancholic MDD subtype represents a particular diagnostic challenge.   
Abbreviations: MDD, Major Depressive Disorder. 
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1. Introduction 
Empirical evidence demonstrates that major depressive disorder 
(MDD) is the most prevalent comorbidity of the immune-mediated, in-
flammatory disease multiple sclerosis (MS) [1]. Compared to the life-
time prevalence of MDD ranging between 12.8% to 17.1% in the general 
community [2–4], prevalence was reported substantially higher in 
persons with MS (PwMS), with the magnitude of difference depending 
on the examined sample (clinical, community/registry-based) and the 
choice of instrument [5,6]: while studies using dimensional screening 
tools with different cut-offs led to lifetime prevalence ranges between 20 
and 50% [e.g., 7, 8–11], studies applying clinical diagnostic interviews 
showed ranges between 17 and 34% [11–13] together with a 12-month 
prevalence of 15.7% [9]. The burden and the consequences of comorbid 
MDD are high and constitute one of the main determinants of decreased 
quality of life in PwMS [14–17]. Thus, the issue of MDD in MS still de-
mands more attention in research and clinical practice [18]. 
MDD is a well-treatable mental disorder [19,20]. However, MDD in 
PwMS is mostly not adequately recognized and hence undertreated 
[18]. The high symptom overlap between MDD and MS represents a 
particular diagnostic challenge and may result in potential distortions of 
MDD prevalence in PwMS [5]. For example, fatigue is one of the most 
common symptoms in MS and, at the same time, represents a major 
diagnostic criterion for MDD, and also psychomotoric retardation and 
sleeping problems occur in both MDD and MS [5]. Furthermore, the 
diagnostic process is hampered by the fact that both MDD and MS bear a 
high symptom heterogeneity. Therefore, apart from the comparison of 
depression symptoms, focusing on homogeneous subtypes (i.e., speci-
fied clusters of differing symptoms) is a promising approach to achieve 
more tailored diagnostics and treatments [21]. 
Studies directly comparing depression symptoms between PwMS and 
persons without MS (Pw/oMS) are still scarce: some studies found that 
MDD in PwMS was characterized by a higher occurrence of either 
neurovegetative or somatic symptoms or health-related concerns and 
suicidal ideation [22–26], whereas other studies, statistically controlling 
for depression severity, concluded that the presentation of depression 
symptoms is highly similar [27,28]. Certain non-somatic depression 
symptoms, such as future pessimism, were also judged to be relevant in 
PwMS [25,29], but these findings were not consistently replicated. 
Apart from the diagnostic threshold level of MDD, the subsyndromal 
symptom ‘irritability’ hallmarking affective instability was also 
emphasized within PwMS [12,30]. 
Evidence is even scarcer regarding depression subtypes. The most 
consistent finding concerns a distinction between melancholic and 
atypical symptom constellations [21,31]; these two depression subtypes 
are also catalogued as MDD specifiers in the fifth edition of the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-5) [32]. The 
melancholic MDD subtype (MDD episode characterized by: a) either loss 
of pleasure or lack of reactivity, and b) three or more of the following 
features: distinct quality of depressed mood, worse in the morning, early 
morning awakening, psychomotor retardation or agitation, anorexia or 
weight loss, excessive guilt) shows a lifetime prevalence of 24–32% 
[33–35] and cumulative incidence rates of 7% [33], the atypical MDD 
subtype (MDD episode characterized by: a) mood reactivity, and b) two 
or more of the following features: weight gain or increase in appetite, 
hypersomnia, leaden paralysis, long-standing pattern of interpersonal 
rejection sensitivity) between 15 and 39% [36–38] and 4% [33], 
respectively. Notably, atypical depression, which is correlated with in-
flammatory processes [39–41] and might particularly benefit from 
specific treatments [41,42], deserves further examination in PwMS. The 
only study so far [29] compared sum scores of atypical and melancholic 
depression symptom clusters between PwMS and Pw/oMS, without 
finding any differences. A potential problem with such clustering algo-
rithms is the overlap in some depressive symptomatology between the 
atypical and melancholic clusters [43]. Consequently, they are not 
defined in their distinct, pure forms, as required by the DSM-criteria. 
Apart from pure melancholic and atypical MDD subtypes, however, 
melancholic and atypical depression subtypes have indeed shown sub-
stantial longitudinal overlap in nearly half of all cases, particularly in 
women [33,34,44,45]. In fact, such defined mixed atypical-melancholic 
MDD subtypes (i.e., persons fulfilling specifiers criteria for both atypical 
and melancholic depression) have not been considered in DSM- 
classifications so far. Because women represent the majority of PwMS 
in most developed countries, the mixed atypical-melancholic MDD 
subtype may also be more prevalent in the population of PwMS and thus 
requires further examination. 
Therefore, the aims of the current study were: 1) to compare 
depression symptoms between PwMS and Pw/oMS; 2) to compare MDD 
subtypes between PwMS and Pw/oMS with a MDD subtype definition 
based on a) distinct pure atypical, pure melancholic, and mixed atypical- 
melancholic MDD subtypes according to DSM-5 criteria [32] and b) 
MDD subtypes based on latent class analysis (LCA), a data-driven 
approach; and 3) to describe these MDD subtypes by depression char-
acteristics and MS characteristics in PwMS. In particular, a more 
frequent occurrence of the atypical MDD subtype / atypical depression 
symptoms in PwMS compared to Pw/oMS was hypothesized, given that 
inflammatory processes play a central role in MS and are thought to be 
involved in atypical depression [39–41]. We also expected that the 
mixed atypical-melancholic MDD subtype showing a female prepon-
derance was relevant in PwMS [33,34,44]. Finally, by applying LCA we 
expected that the atypical, melancholic, and mixed atypical-melancholic 
MDD subtypes would be replicated while retaining the option to detect 
potentially novel MDD subgroups that could be related to MS. 
2. Materials and methods 
2.1. Study sample 
Data were derived from two sources: a) the Swiss Multiple Sclerosis 
Registry (SMSR), and b) the epidemiology survey of the ZInEP project 
(Zürcher Impulsprogramm zur nachhaltigen Entwicklung der Psychia-
trie, i.e. the „Zurich Program for Sustainable Development of Mental 
Health Services“):  
a) The SMSR is an ongoing, prospective, longitudinal observational 
study focusing on the life circumstances of adult PwMS and their 
relatives and proxies in Switzerland (n = 2370; status quo: August 
31, 2020) (http://www.Clinical- Trials.gov identifier: 
NCT02980640). This study was initiated and is funded by the Swiss 
MS Society. The patient-centered SMSR is based on a citizen-science 
approach directly involving PwMS in central functions. Details on 
the study design and evidence of the representativeness of the SMSR 
for the Swiss MS population are described elsewhere [46–48]. For 
the current study, the 12 month post baseline survey data containing 
a focus topic depression (n = 567) was considered. The SMSR was 
approved by the Ethics Committee Zurich (PB-2016-00894) and 
written informed consent was obtained from all participants [46].  
b) The ZInEP epidemiology survey was established in order to generate 
comprehensive data about mental health in the general population of 
adults in the canton of Zurich [49]. This survey was designed as a 
cross-sectional sequel to the longitudinal Zurich Study [50], i.e., age 
and sex structure and instruments were parallelized. It consisted of 
three components: a) a brief telephone screening (n = 9829), b) a 
structured face-to-face-interview of a sample stratified along sex, age 
and mental psychiatric symptoms severity (n = 1500) supplemented 
by self-report questionnaires, and c) a longitudinal survey (n = 227) 
[49]. For the present study, information from the face-to-face- 
interview (n = 1500) was used. 
All subjects with an epidemiological MDD diagnosis at any time in 
the past 12 months minimum were selected from the SMSR (n = 92) and 
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the ZInEP survey (n = 277), leading to an overall sample of 369 
depressed persons. Exclusion criterion was a MS diagnosis in the ZInEP 
survey, not occurring in any participant. In contrast, 4 participants were 
excluded in the SMSR sample, as they did not fulfill the required past 12 
months time-frame of MDD. The detailed composition of the samples 
used for subsequent data analysis is depicted in a flow-chart (Fig. 1). 
2.2. Measurements 
2.2.1. Socio-demographic characteristics 
The socio-demographic variables sex, age, education, urbanicity, 
nationality and civil status were drawn from the SMSR baseline assess-
ment and from the ZInEP screening interview, respectively. 
2.2.2. Depression assessment 
The instruments assessing depression were parallelized between the 
SMSR and the ZInEP survey by using the Mini-SPIKE, a shortened 
version of the SPIKE (Structured Psychopathological Interview and 
Rating of the Social Consequences of Psychological Disturbance for 
Epidemiology – Version 10). This face-to-face-interview, based on the 
DSM criteria, was originally developed within the scope of the Zurich 
Study [50,51]. It covers most psychopathological subthreshold and 
threshold syndromes / disorders for the time span of the last 12 months 
and showed very high validity and inter-rater reliability [49]. This in-
strument was found to have high sensitivity and modest specificity (0.95 
and 0.59, respectively) for MDD [50]. In the SMSR, the Mini-SPIKE was 
implemented as a self-assessment and additional information was 
assessed to also cover the time span before the last 12 months. 
DSM-5 criteria [32] derived from the Mini-SPIKE were applied to 
establish an epidemiological MDD diagnosis. Depression severity was 
computed by the MDD diagnosis criteria sum score ranging from 5 to 9 
symptoms. The atypical and melancholic MDD specifiers were separated 
into a) pure subtypes, and b) mixed subtypes if a person fulfilled both 
atypical and melancholic MDD specifiers criteria (excluding the un-
equivocal specifier criterion ‘mood reactivity’). 
On the symptom level, all DSM-5 MDD classification criteria, sup-
plemented by non-covered symptoms of the atypical MDD and melan-
cholic MDD specifiers, were considered (for a full list, see “Depression 
symptoms.docx” in Supplementary material). The neurovegetative MDD 
criteria were disaggregated as this approach turned out to be beneficial 
in detecting depression subtypes in previous studies [52]. ‘Significant 
weight gain / loss’ was fulfilled if the self-reported weight change within 
one month reached at least 5% of the initial body weight. Finally, the 
symptom ‘irritable/angry’ was added as it was judged to be relevant 
within the assessment of MDD in PwMS [12]. 
In the SMSR, the 7-item Beck Depression Inventory-Fast Screen (BDI- 
FS) [53] was also applied. This self-rating questionnaire assessing cur-
rent subjective burden resulting from depression (time-span: past two 
weeks) has been specifically validated for use in PwMS [54]. The BDI-FS 
counteracts the potentially biased overestimation of MDD prevalence in 
PwMS as it captures depression under exclusion of somatic (that is, MS- 
overlapping and therefore likely confounding) features. Clinically sig-
nificant depressive symptomatology was defined as a BDI-FS sum score 
greater than or equal to 4 as this cut-off showed sensitivity between 0.97 
and 1.00 and specificity between 0.79 and 0.99 [55,56]. 
A visual analogue scale (VAS) ranging from 0 (no burden at all) to 
100 (maximal burden) was available from the Mini-SPIKE for both 
surveys, and analyzed both metric and dichotomized by high burden 
(larger than or equal to 75) versus low burden (lower than 75). 
Information on additional clinical and health-related characteristics 
of depression and MS can been found in the Supplementary material (see 
“Clinical and health-related characteristics.docx”). 
2.3. Statistical analysis 
The analysis design comprised two steps: In the first step, the pure 
and mixed MDD subtypes and depression symptoms based on DSM-5 
definitions were compared in the overall sample of depressed PwMS 
and Pw/oMS by regression analysis. These regression analyses were 
adjusted for confounders – both theoretically and empirically derived 
ones. In the second step, LCAs on 19 depression symptoms and a variable 
assessing subjective burden were applied. Latent class characterization 
was based on odds ratios (ORs) with 95% confidence intervals (CI) from 
multivariate multinomial logistic regressions and performed based on 
both the overall sample and restricted only to PwMS. Further details of 
these steps are described in the Supplementary material (see “Regression 




Exclusion criteria  
- MS diagnosis 
0
Major depressive disorder diagnosis: 96 
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Major depressive disorder diagnosis 








Analysis on the overall sample 
369 
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Regression Analysis 





Fig. 1. Flow chart describing the study samples of the Swiss Multiple Sclerosis Registry and the ZInEP epidemiology survey (numbers reflect numbers of persons).  
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analysis and latent class analysis.docx”). Additional sensitivity analysis 
was performed with the variables antidepressant or psychotherapy 
treatment (overall), and DMT (PwMS) due to their potential effect on 
MDD presentation. In descriptive and regression analyses, we took into 
account the stratification of the ZInEP sample. 
Descriptive analysis and regression models were performed using the 
IBM SPSS Statistics for Macintosh, version 25.0 [57] and Stata software 
for Macintosh, version 13.1 [58]. SAS Version 9.4 was used in analyses 
accounting for the stratification of the ZInEP sample. LCA was con-
ducted using Mplus for Macintosh, version 8 [59]. Statistical signifi-
cance was defined as a p-value <0.05. 
3. Results 
3.1. Descriptive statistics 
The comparisons between depressed PwMS and Pw/oMS concerning 
socio-demographics are presented in Table 1. The groups were socio- 
demographically comparable apart from the following significantly 
differing characteristics: the sample of depressed PwMS encompassed 
more women (80.4% vs. 58.2%) and, moreover, a higher age compared 
with Pw/oMS (median: 49.0 vs. 29.0). Additionally, PwMS were more 
frequently married or in a registered partnership (47.3% vs. 25.4%). 
Consequently, the socio-demographic variables sex, age and civil status 
were considered confounding variables, in additional to the theoretical- 
derived confounding variable depression severity, in all subsequent 
regression analyses on PwMS versus Pw/oMS (see Tables 3 and 5). 
The past 12-month prevalence rate of MDD was higher in PwMS (n =
92; 16.2%) compared to Pw/oMS (n = 277; 11.6%, weighted) showing 
the following proportions for PwMS / Pw/oMS: OR = 1.5 (95% CI =
1.1–2.0; unadjusted), and OR = 1.2 (95% CI = 0.9–1.7; adjusted for sex 
and age) (data not tabulated). 
MDD subtypes, and MDD- and somatic characteristics are shown in 
Table 2. The pure atypical and melancholic MDD subtypes according to 
DSM-5 were similarly distributed between PwMS and Pw/oMS. The sum 
scores of the melancholic and atypical specifier criteria and of the 
overall depression symptoms, respectively, were also comparatively 
distributed. However, the mixed atypical-melancholic MDD subtype was 
significantly higher in PwMS (n = 46; 50%) than in Pw/oMS (n = 122; 
35.1%, weighted). The Body Mass Index (BMI) also significantly differed 
between the samples with PwMS showing a higher BMI in comparison 
with Pw/oMS. In contrast, antidepressant and psychotherapeutic treat-
ment and the subjective burden resulting from depression did not differ 
between PwMS and Pw/oMS. Finally, information on the temporal order 
Table 1 
Socio-demographic characteristics of persons with MS (PwMS) and persons 
without MS (Pw/oMS) fulfilling the criteria for a 12-month MDD diagnosis.   
PwMS (n = 92) Pw/oMS (n = 277) 
Socio-demographics   
Sex   
Men 18 (19.6%) 122 (41.8%a) 
Women 74 (80.4%) 155 (58.2%a) 




Educationb   
low 48 (53.9%) 136 (51.1%a) 
high 41 (46.1%) 141 (48.9%a) 
1  
Urbanicityc   
Urban 52 (56.5%) 165 (55.5%a) 
Rural 40 (43.5%) 112 (44.5%a) 
Nationality   
Swiss 86 (93.5%) 258 (90.4%a) 
Other 6 (6.5%) 19 (9.6%a) 
Civil status   
Married, registered partnership 43 (47.3%) 57 (25.4%a) 
Other 48 (52.7%) 220 (74.6%a) 
2  
Results are shown as numbers (percentage), or medians (interquartile range 
(25PI;75PI)). 
Pw/oMS: Zurich (more than 400′000 residents) and Winterthur (more than 
100′000 residents) were considered as urban areas, all other communities as 
rural areas. 
1n=3 missing;2n=1 missing 
Abbreviations: MDD = Major Depressive Disorder; PwMS = Persons with Mul-
tiple Sclerosis; Pw/oMS = Persons without Multiple Sclerosis. 
a weighted relative percentage according to ZInEP stratification. 
b High: High school or higher corresponding to 12–13 years of education. 
c PwMS: based on the Federal Statistical Office of Switzerland; areas classified 
as ‘urban to rural’ were defined as rural. 
Table 2 
MDD subtypes, MDD characteristics and somatic characteristics of persons with 
MS (PwMS) and persons without MS (Pw/oMS) fulfilling the criteria of a 12- 





MDD subtypes (DSM-5 criteria)   
12-month prevalence   
Pure atypical 4 (4.3%) 21 (8.4%a) 
Pure melancholic 21 (22.8%) 62 (27.5%a) 
Mixed atypical-melancholic 46 (50.0%) 122 (35.1%a) 
Not assignable 21 (22.8%) 72 (29.0%a) 
Sum of melancholic specifier criteria 3.0 (2.0;4.0) 3.0 (2.0;4.0a) 
Sum of atypical specifier criteria 2.0 (1.0;3.0) 1.5 (1.0;2.0a) 
MDD characteristics   
Subjective burden resulting from 





Sum score of depressive symptoms   
5 to 9 7.0 (6.3;8.0) 7.0 (6.0;8.0a) 
Treatment   
Antidepressants   
yes 24 (26.1%) 92 (33.0%a) 
no 68 (73.9%) 185 (67.0%a) 
Psychotherapy   
yes 34 (37.0%) 102 (28.7%a) 
no 58 (63.0%) 175 (71.3%a) 
Antidepressants or Psychotherapy   
yes 45 (48.9%) 126 (42.0%a) 
no 47 (51.1%) 151 (58.0%a) 
Somatic characteristic   
Body Mass Index 25 (22.0;28.9) 23 (20.7;25.3a) 
2 3 
Additional depression characteristics   
Only available for PwMS   
BDI-FS   
Clinically relevant depressive 
symptomatology 
53 (57.6%) N/A 
4  
Temporal order of depression with MS 
diagnosis  
N/A 
Before 4 (4.7%)  
After 46 (54.1%)  
At the same time 6 (7.1%)  
Both before and after 29 (34.1%)  
5  
WHO-Five Well-being index  N/A 
Sum score 12 (9.0;16.0)  
Good well-being 40 (46.0%)  
Poor well-being, indication for testing MDD 
given 
47 (54.0%)  
6  
Results are shown as numbers (percentage), or medians (interquartile range 
(25PI;75PI)). 
1n=3 missing;2n=3 miss;3n=2 miss;4n=6 missing;5n=7 miss;6n=5 miss 
NA = not applicable. 
Abbreviations: PwMS = Persons with Multiple Sclerosis; Pw/oMS = Persons 
without Multiple Sclerosis; MDD = Major Depressive Disorder; BDI-FS = Beck 
Depression Inventory-Fast Screen for Medical Patients; WHO = World Health 
Organization. 
a Weighted relative percentage according to ZInEP stratification. 
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of depression and MS, BDI-FS scores and the WHO-Five Well-being index 
was only available for PwMS: 58% of the group of PwMS reached the 
threshold for clinically relevant depressive symptomatology; more than 
half (54%) of the PwMS confirmed that the depression occurred after the 
MS diagnosis, while around one third responded that the depression 
occurred both before and after the MS diagnosis; and 54% of the PwMS 
had a poor well-being (Table 2). 
The MS characteristics (such as MS form, time since MS diagnosis, 
disease modifying therapies (DMT), current relapses, EDSS proxy mea-
sure, MS symptoms and mobility) and health-related quality of life of 
depressed PwMS compared to non-depressed PwMS are depicted in the 
Supplementary material (see “Table 1. docx”). Depressed PwMS re-
ported a significantly lower health-related quality of life and a signifi-
cantly higher frequency of symptoms with a substantial individual 
burden such as fatigue or weakness. 
3.2. MDD subtypes and depression symptoms based on DSM-5 
Table 3 displays the unadjusted and adjusted ORs with 95% CI from 
the univariable and multivariable logistic regression analyses focusing 
on pure and mixed MDD subtypes and depression symptoms according 
to DSM-5. The risk for PwMS to fulfill the criteria for the mixed atypical- 
melancholic MDD subtype was around twofold higher in comparison to 
Pw/oMS. 
Regarding specific depression symptoms, the PwMS depicted a 
higher risk for the depression symptoms ‘weight gain’ being ‘irritable, 
angry’, and ‘leaden paralysis’ (i.e., heavy, leaden feelings in arms or 
legs) after adjustment. The depression symptoms ‘weight gain’ and 
‘leaden paralysis’ associated with PwMS represent somatic atypical 
MDD subtype criteria, however, the full set of criteria (pure atypical 
MDD subtype) did not significantly differ between the samples (Table 3). 
These results also remained stable even after additional adjustment 
for the not significantly differing sociodemographic variables education, 
urbanicity, and nationality, and antidepressant or psychotherapy treat-
ment (overall), as well as DMT (PwMS) (data not shown). 
The higher risk for ‘psychomotor retardation’, ‘early-morning 
awakening’, ‘worse in the morning’, ‘taedium vitae, suicidal thoughts/ 
attempt’, and ‘no mood reactivity’ in PwMS was no longer significant 
after adjustment (Table 3). 
3.3. Depression subtypes derived by LCA 
3.3.1. Selection of a LCA model 
For the selection of a final LCA model, the statistical fit indices, the 
aspect of parsimony and the theoretical interpretability were taken into 
account. Based on the combination of optimal statistical fit indices and 
the aspect of parsimony, the two-, three-, and four class LCA models 
were chosen for further consideration (Table 4). For more insight into 
the theoretical interpretability, these LCA models were plotted 
(Figures not shown): in the two-class model, the two latent classes 
mainly differentiated between more and less severe depression. From 
the three-class model on, the hypothesized theoretical framework with 
atypical and melancholic depression profiles were discriminable. The 
four-class model, however, led to extreme and clinically not meaningful 
estimates (so called boundary estimates). Under consideration of all 
these statistical and theoretical aspects, the three-class model was 
therefore chosen and implemented in further analyses. 
3.3.2. Labeling of the three latent classes 
Fig. 2 depicts the selected three-class LCA model. The different 
colored plots show the estimated probabilities (y-axis: 0 to 1) of the 
three classes manifesting the corresponding depression symptom (x- 
axis). This thus provided class-specific depression symptom profiles on 
all depression symptoms. In other words, every class contained a group 
of persons with similar depression symptom profiles and the three plots 
represent the overall depression symptom profiles of classes one to 
three. In this three-class LCA model, two severe classes (class 1 (blue) 
and class 2 (red)) with high probabilities for most depression symptoms 
were distinguishable from the less severe class (class 3 (green)): The 
Table 3 
Odds ratios and confidence intervals (95%) from univariable and multivariable 
logistic regressions for the overall MDD sample (n = 369) depicting the risk of 
persons with MS (PwMS) versus persons without MS (Pw/oMS) to show a spe-
cific MDD subtype and depression symptom.   
PwMS versus Pw/ 
oMS (weighted) 
(ref.) 
PwMS versus Pw/oMS 
(weighted) (ref.) 
Unadjusted Adjusted for sex, age, 
depression severity and 
civil status 
MDD subtypes (DSM-5 
criteria)   
12-month prevalence   
Pure atypical 0.55 (0.15–1.59) 0.97 (0.30–3.10) a 
Pure melancholic 0.78 (0.42–1.44) 0.48 (0.17–1.38) a 
Mixed atypical melancholic 1.85 (1.12–3.03) 2.22 (1.03–4.80)a 
Depression symptoms   
Depressed mood 1.01 (0.37–2.72) 1.15 (0.11–11.63) 
Anhedonia, loss of interest/ 
activity 
5.07 (0.59–43.52) 2.27 (0.19–27.04) 
Fatigue, loss of energy 0.93 (0.37–2.40) 0.65 (0.07–1.37) 
Psychomotor retardation 2.48 (1.48–4.17) 1.29 (0.68–2.44) 
Psychomotor agitation 0.86 (0.50–1.49) 1.21 (0.49–2.95) 
Early-morning awakening 2.41 (1.43–4.07) 1.42 (0.62–3.26) 
Worse in the morning 1.76 (1.02–3.04) 1.58 (0.65–3.85) 
Hypersomnia 0.82 (0.49–1.41) 1.12 (0.46–2.72) 
Weight loss 0.61 (0.23–1.66) 0.57 (0.14–2.29) 
Weight gain 3.95 (1.37–11.65) 6.91 (2.20–21.70) 
Loss of appetite 0.71 (0.42–1.21) 0.52 (0.22–1.24) 
Increased appetite 1.43 (0.83–2.46) 2.17 (0.90–5.22) 
Irritable, angry 1.55 (0.87–2.76) 3.18 (1.08–9.39) 
Hypersensitivity to critical 
remarks 
0.66 (0.39–1.12) 0.48 (0.20–1.18) 
Leaden paralysis 4.09 (2.39–6.99) 3.03 (1.35–6.82) 
Feelings of inferiority, loss of 
self-confidence, guilt 
0.89 (0.44–1.80) 0.42 (0.10–1.75) 
Concentration/memory 
problems, difficulties in 
decision making 
0.78 (0.34–1.78) 0.98 (0.25–3.88) 
Taedium vitae, suicidal 
thoughts/attempt 
1.77 (1.08–2.93) 1.02 (0.35–2.96) 
No mood reactivity 1.76 (1.08–2.89) 1.43 (0.62–3.28) 
Depression characteristic   
Subjective burden resulting 
from depression (0–100, cut- 
off ≥75) 
1.21 (0.71–2.06) 1.45 (0.58–3.61) 
Bold indicates significant Odds Ratios (p < 0.05). 
Abbreviations: MDD = Major Depressive Disorder; ref.: reference. 
a No adjustment for depression severity as number of symptoms is an inherent 
feature of the mixed and pure depression subtype diagnoses. 
Table 4 
Model fit indices derived from unconditional latent class analysis with classes 
ranging from 1 to 5 based on the overall MDD sample (n = 369) including 
persons with MS (PwMS) (n = 92) and persons without MS (Pw/oMS) (n = 277).  
Fit statistics Class 1 Class 2 Class 3 Class 4 Class 5 
AIC 7615.214 7473.845 7441.327 7416.552 7404.213 
BIC 7693.429 7634.187 7683.797 7741.148 7810.936 
ABIC 7629.977 7504.109 7487.092 7477.818 7480.980 
Entropy N/A 0.570 0.704 0.770 0.803 
LMR-LRT, 
adj. 
N/A p < 0.001 p = 0.1184 p = 0.1606 p = 0.4458 
NA, not applicable. 
Abbreviations: MDD = Major Depressive Disorder; AIC = Akaike Information 
Criterion; BIC = Bayesian Information Criterion; ABIC = Sample-Size Adjusted 
Bayesian Information Criterion; LMR-LRT adj. = Lo-Mendell-Rubin likelihood 
ratio test, adjusted. 
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estimated probabilities illustrate that the severe class 1 (n = 151) 
showed a predominantly melancholic depression symptom profile, 
therefore it was labeled ‘melancholic’. In contrast, the severe class 2 (n 
= 86) included individuals with both high probabilities of atypical, i.e., 
reversed vegetative depression symptoms, and melancholic depression 
features. Due to its mixed symptom profile, this class was labeled ‘mixed 
atypical-melancholic’. Finally, class 3 (n = 132) was labeled ‘moderate’ 
as its depression symptom profile was characterized by less severity, that 
is, lower probabilities for most depression symptoms. 
3.3.3. Overall: characterization of the three latent classes 
Relevant characteristics of the three latent classes of the overall 
sample of subjects with MDD are shown in Table 5. PwMS and women 
had a higher risk of belonging to the ‘mixed atypical-melancholic’ class. 
Both severe classes (‘mixed atypical-melancholic’ and ‘melancholic’) 
were additionally associated with more antidepressants or psychother-
apy treatment in comparison to the moderate class. However, neither 
age nor civil status were significantly associated with one of the severe 
latent classes (Table 5). 
3.3.4. PwMS: characterization of the three latent classes 
Focusing only on PwMS, the ‘melancholic’ class but not the ‘mixed 
atypical-melancholic’ class was associated with a significantly higher 
risk for clinically relevant depressive symptomatology assessed by the 
BDI-FS compared to the ‘moderate’ class (Table 6). Both severe classes 
were associated with a high subjective burden resulting from depres-
sion. In contrast, female sex and antidepressant or psychotherapeutic 
treatment were not significantly associated with the ‘melancholic’ or the 
‘mixed atypical-melancholic’ classes. Also with regard to the MS-related 
variables time since MS diagnosis, total number of relapses, and EDSS 
proxy measure, no significant associations characterizing the ‘melan-
cholic’ or the ‘mixed atypical-melancholic’ class were found (Table 6). 
4. Discussion 
This nationwide Swiss MS registry study provides new important 
insight into MDD in PwMS by characterizing and comparing MDD 
subtypes and depression symptoms with a community-based sample of 
depressed Pw/oMS. We found that MDD in PwMS was characterized by 
a higher risk of somatic atypical depression symptoms, but not for the 
pure atypical MDD subtype. Moreover, we demonstrated for the first 
time that the mixed atypical-melancholic MDD subtype was linked to 
PwMS. This MDD subtype occurred in 50% of all PwMS and comprised a 
high overlap with MS-inherent disease characteristics, thus representing 
a particular challenge from a diagnostic point of view. 
4.1. MDD subtypes 
PwMS were more likely than Pw/oMS to develop the mixed atypical- 
melancholic MDD subtype (i.e., fulfilling the criteria for both the 
Fig. 2. Unconditional three-class model derived from latent class analysis on the overall MDD sample (n = 369).  
Table 5 
Odds ratios and confidence intervals (95%) from multivariable multinomial 
logistic regressions characterizing the empirically derived latent classes on the 
overall MDD sample (n = 369).   
Melancholic (n ¼
151) 
versus moderate (n 
¼ 132) (ref.) 
Mixed atypical- 
melancholic (n ¼ 86) 
versus moderate (n ¼
132) (ref.) 
MS Diagnosis   
Persons with MS (PwMS) 1.74 (0.74–4.08) 2.59 (1.01–6.64) 
Persons without MS (Pw/ 
oMS) 
ref. ref. 
Socio-demographics   
Sex   
Women 0.97 (0.58–1.61) 1.93 (1.03–3.59) 
Men ref. ref. 
Age 0.99 (0.96–1.02) 0.97 (0.94–1.01) 
Civil status   




Depression characteristics   
Antidepressants or 
psychotherapy   
yes 3.47 (2.09–5.77) 2.28 (1.27–4.09) 
no ref. ref. 
Bold indicates significant Odds Ratios (p < 0.05). 
Missing latent classes: melancholic: n = 1. 
Abbreviations: MDD = Major Depressive Disorder; MS = Multiple Sclerosis; 
PwMS = Persons with Multiple Sclerosis; Pw/oMS = Persons without Multiple 
Sclerosis; ref.: reference. 
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atypical and the melancholic depression subtypes), which is in line with 
our hypothesis. This was not only shown by the subtyping of pure versus 
mixed DSM-5 criteria, but also successfully replicated by the data-driven 
approach. 
The occurrence of the severe mixed atypical-melancholic MDD sub-
type in half of all PwMS is in parallel with earlier work on Pw/oMS 
showing that this subtype is common. Moreover, these studies found 
more comorbid disorders, higher depression severity, and a female 
preponderance of this MDD subtype [33,34,44]. Evidence regarding the 
high depression severity of this MDD subtype was reflected in its defi-
nition requiring the criteria of two different MDD subtypes, and by the 
fact, that it was clearly distinguishable from a MDD subtype with 
moderate severity in the data-driven approach. Such severity differences 
of MDD subtypes are consistent with previous studies demonstrating 
that apart from symptom patterns, also severity contributes to explain 
the heterogeneity of MDD [e.g., 45, 52, 60, 61]. 
The mixed atypical-melancholic MDD subtype was particularly 
characterized by a large number of somatic depression symptoms. In 
fact, this MDD subtype showed a remarkably high overlap with inherent 
features of the MS disease, such as ‘psychomotor retardation’, ‘sleep 
disturbances’, and ‘leaden paralysis’. Accordingly, one might assume 
that the mixed atypical-melancholic MDD subtype mainly reflects a 
higher MS-inherent disability. However, this was not indicated in our 
results among PwMS as the EDSS proxy measure [62], time since MS 
diagnosis and total number of relapses did not differ between the severe 
and moderate MDD subtypes. Considering the high probability of 
somatic depression symptoms in the mixed atypical-melancholic MDD 
subtype, we found that the screening instruments commonly applied for 
PwMS were somewhat limited due to the exclusion of somatic depres-
sion symptoms as in the BDI-FS [5]. We do not question the appropri-
ateness of the BDI-FS as a screening instrument for PwMS, it is simply 
less sensitive with respect to this particular MDD subtype in our study 
despite the high subjective burden and high probabilities for the main, 
non-somatic MDD criteria and ‘suicidality’ of these persons. Conse-
quently, an accurate depression diagnosis might present a particular 
challenge within PwMS with the mixed atypical-melancholic MDD 
subtype bearing the risk of false negatives in clinical practice. The 
alternative explanation that PwMS more often develop mixed atypical- 
melancholic depression states merely due to the preponderance of 
women [44] is insufficient in this study, as the association remained 
significant even after adjustment for sex. In fact, this is a remarkable 
finding. We speculate that the high occurrence of the mixed atypical- 
melancholic MDD subtype in PwMS might be the result of, multicausal 
factors (such as inflammatory processes, reactive depression since the 
MS diagnosis and during the progression of the disease, collateral 
depression due to neuroinflammation /− degeneration) manifesting in a 
mixed rather than a pure MDD subtype. In any case, this MDD subtype, 
which not yet been categorized in DSM-5, deserves more attention in 
future research. 
Contrary to our expectations, the atypical MDD subtype was neither 
more prevalent in PwMS nor replicated in the data-driven approach. 
However, as the pure MDD subtype derived by the DSM-5 criteria 
depicted the smallest group of depressives, it was probably statistically 
incorporated in the mixed atypical-melancholic MDD subtype in the 
three-class LCA solution of the data-driven approach. Therefore, our 
result distinguishing between pure and mixed MDD subtypes was in 
accordance with the study of Boeschoten et al. [29] not finding any 
difference of atypical depression clusters between PwMS and Pw/oMS, 
but at the level of depression symptoms. 
4.2. Depression symptoms 
In contrast to the lacking prevalence differences between PwMS and 
Pw/oMS relating to the atypical MDD subtype, differences were present 
in terms of atypical depression symptoms. Hence, this finding partially 
added weight to our hypothesis, as we also expected more atypical 
symptoms in PwMS compared to Pw/oMS. In our study, PwMS yielded a 
higher risk for the two somatic atypical depression symptoms ‘leaden 
paralysis’ and ‘weight gain’ and the symptom ‘irritable/angry’. These 
symptoms were all especially pronounced in the mixed atypical- 
melancholic MDD subtype. Thus, our results corroborate previous 
findings by highlighting the relevance of somatic or neurovegetative 
depression symptoms in PwMS [22–25]; this held also after adjustment 
for sex, age, civil status and depression severity. 
In contrast to Boeschoten et al. [29], ‘leaden paralysis’ thus reached 
the level of significance even after adjustment in the current study. In 
several other reports, information on ‘leaden paralysis’ was lacking, as 
depression symptoms were assessed by the BDI omitting this symptom 
[22–24,27,28]. Although ‘leaden paralysis’ has been defined as a core 
feature of atypical depression in several concepts [63], this symptom is 
particularly difficult to disentangle from MS-related fatigue and de-
serves more attention in this specific population. Concerning the higher 
occurrence of ‘weight gain’, the finding of a recent study [64] is inter-
esting: the leading symptom for the association between depression and 
inflammatory and metabolic markers was ‘increased appetite’. 
‘Increased appetite’ correlates to ‘weight gain’. However, it remains 
uncertain whether a comparable association with inflammation would 
occur for ‘weight gain’. Again our finding differed from another study 
[29] where ‘weight gain’ was not associated with MS. This might result 
from the different time-frames considered for the assessment of the 
depression symptoms: past week interval in the latter study [29], past 
12-months in the current study. 
Table 6 
Odds ratios and confidence intervals (95%) from multivariable multinomial 
logistic regressions restricted to the sample of PwMS (n = 92) characterizing the 
empirically derived latent classes on the overall MDD sample (n = 369).   
Melancholic (n ¼ 38) 
versus moderate (n ¼
29) (ref.) 
Mixed atypical- 
melancholic (n ¼ 25) 
versus moderate (n ¼ 29) 
(ref.) 
Socio-demographics   
Sex   
Women 4.43 (0.61–32.20) 2.83 (0.35–23.03) 
Men ref. ref. 
Depression 
characteristics   




6.30 (1.42–27.91) 3.08 (0.65–14.64) 
Antidepressants or 
Psychotherapy   
yes 3.26 (0.74–14.35) 1.56 (0.32–7.48) 
no   
Subjective burden 
resulting from 
depression   
0–100 1.05 (1.00–1.11) 1.08 (1.02–1.14) 
MS characteristics   
Time since MS 
diagnosis 
0.99 (0.92–1.07) 0.99 (0.91–1.08) 
Relapsesa 
(total number, lifetime) 
0.96 (0.86–1.07) 0.95 (0.85–1.06) 
EDSS proxy measureb 
(cut-off: ≥ 4) 
0.63 (0.12–3.42) 0.62 (0.10–3.75) 
Bold indicates significant Odds Ratios (p < 0.05). 
Abbreviations: MDD = Major Depressive Disorder; BDI-FS = Beck Depression 
Inventory-Fast Screen for. 
Medical Patients; PwMS = Persons with Multiple Sclerosis; EDSS = Expanded 
Disease Status Scale. 
a Without n = 8 persons with PPMS. 
b (Kaufmann et al., 2020) Kaufmann M, Salmen A, Barin L, et al. (2020) 
Development and validation of the self-reported disability status scale (SRDSS) 
to estimate EDSS-categories. Mult Scler Relat Disord 42: doi:https://doi.org/10 
.1016/j.msard.2020.102148. 
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Apart from the two somatic atypical depression features, the symp-
tom ‘irritable/angry’ was also more frequently present in depressed 
PwMS than in depressed Pw/oMS. This symptom does not belong to the 
regular MDD criteria. However, studies have emphasized that it char-
acterizes depression in PwMS, which is possibly explainable by MS- 
related cerebral changes crucial for the maintenance of cognitive as 
well as emotional stability [12,25,65–68]. 
4.3. Limitations 
This research is subject to several limitations. First, a limitation 
pertains to the general recall bias of self-reported data. Second, the Mini- 
SPIKE was applied as a self-rating questionnaire due to the general 
methodological approach of the SMSR. Thus, MDD prevalence in PwMS 
is expected to be underestimated in the SMSR since prevalence rates of 
mental disorders are likely lower if not assessed in face-to-face settings. 
Third, information on further psychopathological comorbidities, such as 
bipolar depression, has been omitted in this analysis despite its rele-
vance in atypical depression [69]. Notably, the symptom ‘irritable/ 
angry’ is relevant in bipolar disorders [70], but also within the pre-
menstrual syndrome [71]. Finally, the cross-sectional design hinders 
causal conclusions concerning the temporal order of MDD, depression 
symptoms and MS. 
4.4. Conclusions and outlook 
The results of our study indicated that differences in MDD between 
PwMS and Pw/oMS resulted from the higher risk of PwMS for somatic 
atypical depression symptoms and the mixed atypical-melancholic MDD 
subtype. However, we found no differences between PwMS and Pw/oMS 
regarding the pure atypical MDD subtype. In fact, the somatic atypical 
depression symptoms were particularly pronounced in the mixed 
atypical-melancholic MDD subtype. As inflammation represents a core 
biological correlate of atypical depression [39] we thus cannot ascertain 
that MDD in PwMS may be linked to the MS-disease inherent inflam-
mation. Even though immunological anomalies were judged to explain 
only a small proportion of the overall variance between MDD and MS 
[72], additional research on this topic is required. Important evidence 
was gained pertaining to the mixed atypical-melancholic MDD subtype: 
this group depicted a high overlap with MS features and thus represents 
a particular diagnostic challenge for health-care professionals. We 
cannot provide any etiopathogenetic explanations for the predominance 
of the mixed atypical-melancholic MDD subtype in PwMS nor clearly 
assign the overlapping features to either disease. However, we conclude 
that these features are obviously constitutive for this MDD subtype in 
PwMS and, moreover, crucially associated with high subjective burden. 
These research findings are important for the persons comorbidly 
affected by the two heterogeneous disorders MS and MDD. Last but not 
least, these results may provide the basis for advancing more specific 
pharmacological and psychological treatment strategies. 
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